TD Cowen analyst Joseph Thome has maintained their bullish stance on QURE stock, giving a Buy rating on March 4.
Joseph Thome has given his Buy rating due to a combination of factors that highlight uniQure’s promising position in the biotechnology sector. The company’s development of AMT-130, a gene therapy for Huntington’s disease, has made significant strides, particularly with the FDA’s alignment on an accelerated approval pathway. This strategic alignment is expected to expedite the approval process, bypassing the need for a large Phase III trial, and instead utilizing data from ongoing Phase I/II studies.
Moreover, recent data has shown promising results, with AMT-130 demonstrating a significant slowing of disease progression compared to external controls. The company’s management has expressed strong confidence in their ability to assemble an approvable BLA package and successfully launch the therapy in the U.S. if approved. The potential market opportunity for AMT-130 is substantial, and with the stock currently undervalued, Thome sees a significant upside potential, reinforcing his Buy recommendation.
Thome covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, PTC Therapeutics, and uniQure. According to TipRanks, Thome has an average return of 2.0% and a 37.89% success rate on recommended stocks.
In another report released on March 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.